focus -WSS

focus

author：explore 2025-09-06 04:38:42 - browse：969

A liver with a smooth and healthy left half and a bumpy, browning right half — chronic disease coverage from STAT — Adobe

Akero Therapeutics said Monday that extending treatment with its experimental drug for the liver disease known as MASH from six months to two years resulted in better outcomes for patients — most notably reductions in liver scarring at a rate three times higher than placebo without worsening other symptoms.

The mid-stage study of the Akero drug called efruxifermin achieved its main goal in September 2022. With longer treatment, more patients with MASH responded to the drug, while those who initially benefited showed durable improvements.

“We’re really pleased with the data. It’s exactly what we were hoping to see,” said Kitty Yale, Akero’s chief development officer, in an interview with STAT. “It’s not just the high response rates, but the fact that responses are sustained and broadened as well.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Information blocking fines are now fair game in health care

entertainment

WSS

The struggle to figure out which patients 'deserve' Wegovy

Decentralized clinical trials need collaboration to achieve wider use

J&J reports mixed data on next

New research sheds light on how often breast cancer is overdiagnosed

Chamber of Commerce, DOJ clash in court over drug prices

Clinicians often fail to acknowledge the pain caused by long Covid

entertainment

focus

hotspot

Medicare details structure of new drug price negotiation program

Why the drug industry's warnings on the IRA's impact fall short

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Congress: Prevent baby formula shortages by passing a new bill

Psychedelics group wrestles with new pharma identity

Free Covid tests will again be offered to all U.S. households

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Akili changes sales model for its ADHD video game treatment

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Should insurance cover cosmetic surgery?

leisure time

FDA panel to weigh safety of artificial wombs for preterm births

Guardant Health colon cancer test endorsed by FDA advisory panel

How the messy conversation about Dolly changed bioethics

The world needs the new pandemic treaty

Free Covid tests will again be offered to all U.S. households

Bubonic plague hit France in 1720. Officials dithered. Sound familiar?

hotspot

entertainment

knowledge

leisure time